Shearman & Sterling is representing Synthes, Inc., a premier global manufacturer of orthopaedic devices, in its definitive agreement to be acquired by Johnson & Johnson, the world’s most comprehensive and broadly-based manufacturer of health care products, in a transaction valued at $21.3 billion. The transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, approval by the European Commission and regulatory approval in certain other jurisdictions, as well as other customary closing conditions.

The Shearman & Sterling team was led by partners Christa D'Alimonte (New York-Mergers & Acquisitions) and Creighton Condon (London-Mergers & Acquisitions) and included partners Paula Howell Anderson (New York-Litigation), Larry Bambino (New York-Tax), John Cannon (New York-Executive Compensation & Employee Benefits), Dale Collins (New York-Antitrust), Alan Goudiss (New York-Litigation), Doug McFadyen (New York-Tax), and Sam Waxman (New York-Intellectual Property Transactions); counsel Lisl Dunlop (New York-Antitrust); and associates James Benson (New York-Mergers & Acquisitions), Tammara Fort (New York-Mergers & Acquisitions), Timothy Franklin (New York-Intellectual Property Transactions), Timothy Haney (New York-Antitrust), Shiu-Kay Hung (New York-Tax), Karina Lubell (Washington, DC-Antitrust), Sean McGrath (New York-Executive Compensation & Employee Benefits), Nadir Nurmohamed (New York-Mergers & Acquisitions), Tiffany Sepulveda (New York-Executive Compensation & Employee Benefits) and Joanna Si (New York-Mergers & Acquisitions).